Analyst Consensus ?
ConsensusHold13 ratings
Bullish430.8%
Neutral861.5%
Bearish17.7%
Viatris Inc. · VTRS · FY2025 Q4 · Calendar Q1 2026
Viatris Maintains Guidance as Savings Fund 2026 Launches
Viatris enters 2026 with maintained guidance, a substantial cost-savings program and several planned launches that could support growth. The evidence is constructive but depends on savings realization, regulatory execution, recovery from the Nashik disruption and offsetting Japan pricing and mix pressure.
Reported Before market openNASDAQHealthcare
$20.33B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.57
Consensus $0.53
EPS surprise
+7.1%
Reported versus consensus
Reported revenue
$3.70B
Consensus $3.53B
Revenue surprise
+4.8%
Reported versus consensus
Market reaction
prior-close to event-session close
Stock move
-5.2%
Event window
SPY move
-0.6%
Same window
Abnormal move
-4.6%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
-12.3%
Up to 20 sessions
VTRSSPY benchmark
Ask FN2 about VTRS FY2025 Q4
Transcript, numbers and history already loaded
Why did VTRS fall 5.2% after beating EPS estimates in FY2025 Q4?What changed in VTRS's guidance and outlook in FY2025 Q4?Give me the bull and bear case for VTRS after FY2025 Q4 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The company moved from raising prior-quarter guidance to maintaining 2026 expectations. It quantified the strategic review at $650 million of gross savings, including $400 million net over three years and $250 million for reinvestment; it also disclosed the Nashik plant fire and a broader 2026 launch and approval slate.
Guidance delta
Guidance was maintained. Management expects modest 2026 revenue and adjusted EBITDA growth, with margin pressure from ARV mix and Japan price erosion partly offset by higher-margin new products.
Key takeaways
- Viatris reported 2025 revenue of $14.3 billion and adjusted EBITDA of $4.2 billion.
- The strategic review identified $650 million of gross cost savings; $400 million net is expected over three years, with $250 million redeployed.
- Planned 2026 launches include Effexor in Japan, a low-dose estrogen weekly patch in the U.S. and fast-acting meloxicam.
- Capital return exceeded $1 billion, while the Nashik plant fire, Japan pricing and product approvals remain key execution risks.
Management priorities
- Deliver the strategic review's cost savings and reinvest up to $250 million in commercial and innovative capabilities.
- Execute 2026 launches for Effexor, the estrogen patch, fast-acting meloxicam and other pipeline assets.
- Pursue six product approvals, phase 3 readouts and targeted business-development transactions.
- Modernize technology, data and talent platforms while strengthening execution across key regions.
Follow VTRS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$17.46Current
$12Low
$17.82Average
$25High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 2, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Piper Sandler | Neutral | Neutral | Maintain | Sep 16, 2026 |
| Argus Research | Buy | Buy | Maintain | Sep 8, 2026 |
| Barclays | Overweight | Overweight | Maintain | May 19, 2026 |
| Truist Securities | Buy | Buy | Maintain | May 8, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | May 8, 2026 |
| Jefferies | Buy | Buy | Maintain | Mar 7, 2025 |
| B of A Securities | Underperform | Underperform | Maintain | Feb 28, 2025 |
| BMO Capital | Market Perform | Outperform | Downgrade | Feb 17, 2023 |
| UBS | Neutral | Sell | Upgrade | Nov 10, 2022 |
| Goldman Sachs | Neutral | Neutral | Maintain | May 12, 2022 |
| Citigroup | Neutral | Neutral | Maintain | Mar 10, 2022 |
| Raymond James | Market Perform | Outperform | Downgrade | Mar 1, 2022 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Mar 10, 2021 |
Named analyst price targets
Upside is calculated against the persisted current price $17.46. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Oppenheimer | Analyst unavailable | $25 | $17.18 | +43.2% | Sep 23, 2026 |
| Leerink Partners | Analyst unavailable | $20 | $16.61 | +14.5% | Sep 9, 2026 |
| Argus Research | Analyst unavailable | $20 | $16.75 | +14.5% | Sep 8, 2026 |
| Barclays | Glen Santangelo | $22 | $16.5 | +26.0% | May 19, 2026 |
| Truist Financial | Analyst unavailable | $20 | $16.94 | +14.5% | May 8, 2026 |
| UBS | Ashwani Verma | $18 | $14.58 | +3.1% | Feb 9, 2026 |
| Piper Sandler | Analyst unavailable | $12 | $13.12 | -31.3% | Jan 28, 2026 |
| Argus Research | Analyst unavailable | $15 | $12.84 | -14.1% | Jan 16, 2026 |
| Truist Financial | Les Sulewski | $16 | $12.4 | -8.4% | Jan 7, 2026 |
| Truist Financial | Analyst unavailable | $15 | $9.93 | -14.1% | Oct 15, 2025 |
| Jefferies | Glen Santangelo | $15 | $11.77 | -14.1% | Jul 19, 2024 |
| Piper Sandler | David Amsellem | $13 | $11.83 | -25.5% | Mar 28, 2024 |
| Piper Sandler | David Amsellem | $10 | $9.84 | -42.7% | Jun 26, 2023 |
| Barclays | Analyst unavailable | $15 | $12.16 | -14.1% | Feb 1, 2023 |
| UBS | Ashwani Verma | $12 | $10.83 | -31.3% | Nov 9, 2022 |
| UBS | Ashwani Verma | $9 | $10.77 | -48.5% | Jun 13, 2022 |
Track every rating change on VTRS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationViatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors.…
Historical context
All VTRS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| COO The Cooper Companies, Inc. | FY2026 Q3 · Calendar Q3 2026 | +2.7% | -14.7% | CooperCompanies beats expectations as inventory reduction weighs on vision revenue |
| MDT Medtronic plc | FY2027 Q1 · Calendar Q3 2026 | +4.3% | +1.5% | Medtronic raises FY27 outlook as growth broadens across platforms |
Latest beats and misses
Who reports nextBeat on EPS
- CAGFY2027 Q1 · September 30, 2026+44.4% EPS-4.9% move
- FDSFY2026 Q4 · September 30, 2026+3.9% EPS+3.8% move
- JBLFY2026 Q4 · September 30, 2026+8.1% EPS-10.0% move
- MUFY2026 Q4 · September 30, 2026+5.4% EPS+0.0% move
- CCLFY2026 Q3 · September 29, 2026+5.9% EPS+13.4% move
- COSTFY2026 Q4 · September 24, 2026+3.2% EPS+2.9% move
Get the VTRS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:36:15.940040+00:00
- Polygon adjusted daily market bars · 2026-10-02T02:36:15.153760+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-02T02:36:15.151152+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-02. For educational purposes only; not investment advice.